In this task, you're given a paragraph and title from the research paper. Your task is to classify whether the given title is suitable or not for the research paper based on the given paragraph. Return "True" if title is proper according to paragraph else "False".

[Q]: Paragraph: The newly identified 2019 novel coronavirus (2019-nCoV) has caused more than 11,900 laboratory-confirmed human infections, including 259 deaths, posing a serious threat to human health. Currently, however, there is no specific antiviral treatment or vaccine. Considering the relatively high identity of receptor-binding domain (RBD) in 2019-nCoV and SARS-CoV, it is urgent to assess the cross-reactivity of anti-SARS CoV antibodies with 2019-nCoV spike protein, which could have important implications for rapid development of vaccines and therapeutic antibodies against 2019-nCoV. Here, we report for the first time that a SARS-CoV-specific human monoclonal antibody, CR3022, could bind potently with 2019-nCoV RBD (KD of 6.3 nM). The epitope of CR3022 does not overlap with the ACE2 binding site within 2019-nCoV RBD. These results suggest that CR3022 may have the potential to be developed as candidate therapeutics, alone or in combination with other neutralizing antibodies, for the prevention and treatment of 2019-nCoV infections. Interestingly, some of the most potent SARS-CoV-specific neutralizing antibodies (e.g. m396, CR3014) that target the ACE2 binding site of SARS-CoV failed to bind 2019-nCoV spike protein, implying that the difference in the RBD of SARS-CoV and 2019-nCoV has a critical impact for the cross-reactivity of neutralizing antibodies, and that it is still necessary to develop novel monoclonal antibodies that could bind specifically to 2019-nCoV RBD. 
 Title: Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus- specific human monoclonal antibody
[A]: False


[Q]: Paragraph: Despite the wide use of Caenorhabditis elegans as a model organism, the first virus naturally infecting this organism was not discovered until six years ago. The Orsay virus and its related nematode viruses have a positive-sense RNA genome, encoding three proteins: CP, RdRP, and a novel δ protein that shares no homology with any other proteins. δ can be expressed either as a free δ or a CP-δ fusion protein by ribosomal frameshift, but the structure and function of both δ and CP-δ remain unknown. Using a combination of electron microscopy, X-ray crystallography, computational and biophysical analyses, here we show that the Orsay δ protein forms a~420-Å long, pentameric fiber with an N-terminal α-helical bundle, a β-stranded filament in the middle, and a C-terminal head domain. The pentameric nature of the δ fiber has been independently confirmed by both mass spectrometry and analytical ultracentrifugation. Recombinant Orsay capsid containing CP-δ shows protruding long fibers with globular heads at the distal end. Mutant viruses with disrupted CP-δ fibers were generated by organism-based reverse genetics. These viruses were found to be either non-viable or with poor infectivity according to phenotypic and qRT-PCR analyses. Furthermore, addition of purified δ proteins to worm culture greatly reduced Orsay infectivity in a sequence-specific manner. Based on the structure resemblance between the Orsay CP-δ fiber and the fibers from reovirus and adenovirus, we propose that CP-δ functions as a cell attachment protein to mediate Orsay entry into worm intestine cells. Orsay, the only virus known to naturally infect the nematode Caenorhabditis elegans, expresses a capsid-δ fusion protein. We have demonstrated that the Orsay fusion protein is incorporated into Orsay capsid and forms a~420-Å long fiber protruding from the PLOS Pathogens | 
 Title: Structure of a pentameric virion-associated fiber with a potential role in Orsay virus entry to host cells
[A]: False


[Q]: Paragraph: Objective To evaluate the efficacy and safety of caffeine citrate in the treatment of apnea in bronchiolitis. Study design Eligible infants aged #4 months presenting to the main pediatric emergency service with apnea associated bronchiolitis were stratified by gestational age (<34 weeks or longer) and randomized to receive a single dose of intravenous 25 mg/kg caffeine citrate or saline placebo. The primary efficacy outcome was a 24-hour apnea-free period beginning after completion of the blinded study drug infusion. Secondary outcomes were frequency of apnea by 24, 48, and 72 hours after study medication, need for noninvasive/invasive ventilation, and length of stay in the hospital's pediatric intensive care/step-down unit. Results A total of 90 infants diagnosed with viral bronchiolitis associated with apnea (median age, 38 days) were enrolled. The rate of respiratory virus panel positivity was similar in the 2 groups (78% for the placebo group vs 84% for the caffeine group). The geometric mean duration to a 24-hour apnea-free period was 28.1 hours (95% CI, 25.6-32.3 hours) for the caffeine group and 29.1 hours (95% CI, 25.7-32.9 hours) for the placebo group (P = .88; OR, 0.99; 95% CI, 0.83-1.17). The frequency of apnea at 24 hours, 24-48 hours, and 48-72 hours after enrollment and the need for noninvasive and invasive ventilation were similar in the 2 groups. No safety issues were reported. Conclusions A single dose of caffeine citrate did not significantly reduce apnea episodes associated with bronchiolitis. (J Pediatr 2016;177:204-11). Trial registration Clinicaltrials.gov: NCT01435486. V iral bronchiolitis is the most common lower respiratory tract infection in infants, leading to 15 hospitalizations per 1000 person-years. Of these, 1.6% to 4% are admitted with apnea. 1-4 Bronchiolitis-associated apnea, a subset of apnea associated with respiratory viruses, appears to be a mixed central and obstructive apnea resulting from a complex interplay of respiratory drive suppression and airway secretions driven by a hyperactive laryngochemoreflex, somnogenic cytokines, and in some cases by virus-specific respiratory suppressant surface proteins. [5] [6] [7] Caffeine is a standard treatment for apnea of prematurity 8,9 and postextubation apnea in preterm infants, 10 and has been used to ameliorate apnea complicating bronchiolitis on the basis of case reports and observational studies. 11-17 Caffeine increases central respiratory drive and chemoreceptor sensitivity to CO 2 and improves skeletal muscle contractions, reducing diaphragm fatigue and leading to better ventilation. 18 Increased metabolic demand, diuresis, tachycardia, dysrhythmias, feeding intolerance, reduced weight gain, and seizures are the reported short-term side effect of caffeine. 19 Although evidence from prospective studies for caffeine used to treat apnea in bronchiolitis is lacking, the drug is commonly used in an attempt to avoid intubation and is considered a standard of care in some institutions. 11,17,20 Thus, we compared blinded intravenous caffeine citrate with placebo for shortening the time to resolution of acute bronchiolitis-associated apnea. 
 Title: Caffeine for the Treatment of Apnea in Bronchiolitis: A Randomized Trial
[A]:
False